New In vivo syngeneic subcutaneous CT26 colon tumor model Shuttle session

07 Sep New In vivo syngeneic subcutaneous CT26 colon tumor model Shuttle session

Because of the success of previous shuttle sessions, which offered the opportunity to run efficacy studies in a cost-saving manner, Explicyte is planning a new shuttle on the CT26 tumor-bearing mouse model, which will take place in October.

In this shuttle, our well-characterized syngeneic CT26 colon tumor-bearing mouse model will be used through standardized study protocols, for the evaluation of potential anti-tumor benefits from drug combinations with reference immune checkpoint inhibitors or chemotherapies.

As cost-effective studies, only experimental test groups will be at the Sponsor’s expense, while vehicle- and reference-treated groups will be covered by Explicyte.

Contact us to book a seat & test your candidate compound.

Shuttle_CT26_Survival

Differential responses of CT26 tumor-bearing mouse model to immune checkpoint inhibitors and to 5-Fluorouracil (5FU) chemotherapy. Mice are challenged with CT26 tumor cells and exposed to either anti-CTLA4, anti-PD1 or anti-PDL1 antibodies, or to 5FU treatment. Contrarily to the strong response to anti-CTLA4 antibody, CT26 tumor is partially responsive to PD1/PDL-1 blockade. A partial response is also observed upon 5FU treatment.

Shuttle for efficacy assessment on 6-week experimental session

·     Model / Strain: CT26 colon tumor-bearing model / Balb/c mice

·     Readouts: Tumor growth / Body weight / Survival

·     Standard reference: PD1, PDL1, or CTLA4 monoclonal antibody, or 5FU treatment

·     Group size: At least 10 mice per group

Optional analyses: Satellite studies for immune response profiling and MoA delineation (flow cytometry, RT-qPCR, immunohistochemistry…). Contact us for further information.

To learn more, Contact us!

contact us

In vivo syngeneic subcutaneous CT26 colon tumor model Shuttle session